Effects of systemic and intra-nucleus accumbens 5-HT2C receptor compounds on ventral tegmental area self-stimulation thresholds in rats.
BACKGROUND
Serotonin 2C (5-HT(2C)) receptors may play a role in regulating motivation and reward-related behaviours. To date, no studies have investigated the possible role of 5-HT(2C) receptors in ventral tegmental area (VTA) intracranial self-stimulation (ICSS).


OBJECTIVE
The current study investigated the hypotheses that 5-HT(2C) receptors play an inhibitory role in VTA ICSS, and that 5-HT(2C) receptors within the nucleus accumbens (NAc) shell may be involved.


METHODS
Male Sprague-Dawley rats were implanted with a VTA electrode and bilateral NAc shell cannulae for the experiment involving microinjections, and trained to respond for electrical self-stimulation. The systemic effects of the selective 5-HT(2C) receptor agonist WAY 161503 (0-1.0 mg/kg), the 5-HT(1A/1B/2C) receptor agonist TFMPP (0.3 mg/kg) and the selective 5-HT(2C) receptor antagonist SB 242084 (1.0 mg/kg) were compared using rate-frequency threshold analysis. Intra-NAc shell microinjections of WAY 161503 (0-1.5 microg/side) were investigated and compared to amphetamine (1.0 microg/side).


RESULTS
WAY 161503 (1.0 mg/kg) and TFMPP (0.3 mg/kg) significantly increased rate-frequency thresholds (M50 values) without altering maximal response rates (RMAX values). SB 242084 attenuated the effects of TFMPP; SB 242084 had no affect on M50 or RMAX values. Intra-NAc shell WAY 161503 had no effect on M50 or RMAX values; intra-NAc amphetamine decreased M50 values.


CONCLUSIONS
These results suggest that 5-HT(2C) receptors play an inhibitory role in regulating reward-related behaviour while 5-HT(2C) receptor activation in the NAc shell did not appear to influence VTA ICSS behaviour under the present experimental conditions.
Hayes
Dave J
DJ
Centre for Neuroscience, 513 HMRC, University of Alberta, Edmonton, AB, Canada T6G 2S2.
Clements
Robert
R
Greenshaw
Andrew J
AJ
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D008297:Male; D008845:Microinjections; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D044405:Receptor, Serotonin, 5-HT2C / Q000378:metabolism*; D012653:Self Stimulation / Q000187:drug effects* / Q000502:physiology; D012684:Sensory Thresholds / Q000187:drug effects* / Q000502:physiology; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology; D017557:Ventral Tegmental Area / Q000187:drug effects* / Q000378:metabolism
D044405:Receptor, Serotonin, 5-HT2C; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists